| Literature DB >> 32375064 |
Nadav I Weinstock1, Daesung Shin1, Narayan Dhimal1, Xinying Hong2, Eric E Irons3, Nicholas J Silvestri1, Chelsey B Reed1, Duc Nguyen4, Oliver Sampson1, Yung-Chih Cheng5, Joseph T Y Lau3, Ernesto R Bongarzone4, Julia Kofler6, Maria L Escolar6, Michael H Gelb2, Lawrence Wrabetz1, M Laura Feltri7.
Abstract
Many therapies for lysosomal storage disorders rely on cross-correction of lysosomal enzymes. In globoid cell leukodystrophy (GLD), mutations in GALC cause psychosine accumulation, inducing demyelination, a neuroinflammatory "globoid" reaction and neurodegeneration. The efficiency of GALC cross-correction in vivo, the role of the GALC substrate galactosylceramide, and the origin of psychosine are poorly understood. Using a novel GLD model, we show that cross-correction does not occur efficiently in vivo and that Galc-deficient Schwann cells autonomously produce psychosine. Furthermore, macrophages require GALC to degrade myelin, as Galc-deficient macrophages are transformed into globoid cells by exposure to galactosylceramide and produce a more severe GLD phenotype. Finally, hematopoietic stem cell transplantation in patients reduces globoid cells in nerves, suggesting that the phagocytic response of healthy macrophages, rather than cross-correction, contributes to the therapeutic effect. Thus, GLD may be caused by at least two mechanisms: psychosine-induced demyelination and secondary neuroinflammation from galactosylceramide storage in macrophages.Entities:
Keywords: GALC; Krabbe disease; Schwann cell; cross-correction; demyelination; galactosylceramide; globoid cell leukodystrophy; hematopoietic stem cell therapy; lysosomal storage disorder; lysosomes; macrophage; psychosine
Mesh:
Substances:
Year: 2020 PMID: 32375064 PMCID: PMC7924901 DOI: 10.1016/j.neuron.2020.03.031
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173